Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Collaborative Integration of HCV Molecular Virology and Mathematical Modeling

Award Number: R01AI078881
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2010
PERIOD OF PERFORMANCE END DATE: 05/31/2025

Group Awards By:

View Award Description

Collaborative Integration of HCV Molecular Virology and Mathematical Modeling - Hepatitis C virus (HCV) is a hepatotropic virus that establishes chronic infection in ~70% of those exposed. As a result, currently more than 71 million people worldwide are infected and at increased risk of developing liver disease and hepatocellular carcinoma. While effective interferon (IFN)-free direct acting antiviral (DAA) therapeutic combinations are highly potent, the promise of DAAs has not yet put us on track to achieve the WHO goal of elimination by 2030. Reaching this goal will require a scaling-up of HCV screening, linkage-to-care, and reduction of treatment cost. Additionally, this will require understanding HCV spread, specifically how to prevent the spread of viral antiviral resistance variants within individuals such that these drug resistance viruses are not transmitted to the population. Importantly, viral cell-to-cell spread has been implicated in antiviral escape, immune escape, and persistence of viruses in general. Thus, the insights gained through the study of HCV should broadly inform future antiviral strategies. Mathematical modeling of HCV in the serum of infected patients during therapy has driven our understanding of HCV infection dynamics, the effect of IFN treatment, and led to methods for the quantitative evaluation of HCV treatment efficacy. Since FDA-approval of HCV DAAs, we have pioneered the development of multiscale models of DAA treatment response in vitro and in patients. This work revealed the dual mechanism of action of NS5A inhibitors and has demonstrated that viral kinetic modeling might allow for a reduction in the duration of DAA therapy in the majority of patients. These clinical insights have been informed by our modeling of HCV infection in cell culture where we are able to directly measure both intracellular and extracellular viral and cellular parameters. Applying both cell culture experimentation and in vivo patient data, we have recently obtained evidence that viral entry/spread plays a major role in the maintenance of steady state infection having broad implications regarding viral spread as an antiviral drug target and how spread impacts antiviral treatment response in terms of drug efficacy, viral escape, and drug synergy. Because these new models have raised important biological questions about HCV spread and antiviral drug strategies, the objective of this cross disciplinary R01 renewal is to enable the improvement of the treatment for HCV and other viruses by formulating and testing mathematical models of HCV infection and treatment response in vivo and in vitro. The specific aims are: 1) Refine and validate time to cure predictions using in vivo and in silico trials; 2) Elucidate quantitative details about the HCV life cycle and the role of hepatocytes in HCV clearance; 3) Expand and optimize mathematical models of HCV cell-to-cell spread; and 4) Determine the importance of cell-to-cell spread as an antiviral drug target.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	13	4/2/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,265,369 )
2025	2025	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	001	14	8/22/2025	EXTENSION WITH OR WITHOUT FUNDS	$1,265,369
2025	2024	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	13	8/22/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,265,369

Issue Date FY: 2024 ( Subtotal = $632,809 )
2024	2024	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	001	13	5/13/2024	NON-COMPETING CONTINUATION	$632,809
2024	2020	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	10	2/2/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $632,809

Issue Date FY: 2023 ( Subtotal = $633,299 )
2023	2023	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	12	5/19/2023	NON-COMPETING CONTINUATION	$633,299
														Subtotal = $633,299

Issue Date FY: 2022 ( Subtotal = $653,884 )
2022	2022	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	001	11	6/3/2022	COMPETING CONTINUATION	$653,884
2022	2020	LOYOLA UNIVERSITY OF CHICAGO	2160 S 1ST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	10	11/3/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $653,884

Issue Date FY: 2020 ( Subtotal = $599,360 )
2020	2020	LOYOLA UNIVERSITY OF CHICAGO	2160 S FIRST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	10	11/26/2019	NON-COMPETING CONTINUATION	$599,360
														Subtotal = $599,360

Issue Date FY: 2019 ( Subtotal = $573,681 )
2019	2019	LOYOLA UNIVERSITY OF CHICAGO	2160 S FIRST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	001	9	4/16/2019	SUPPLEMENT FOR EXPANSION	$42,299
2019	2019	LOYOLA UNIVERSITY OF CHICAGO	2160 S FIRST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	9	11/27/2018	NON-COMPETING CONTINUATION	$531,382
														Subtotal = $573,681

Issue Date FY: 2018 ( Subtotal = $531,387 )
2018	2018	LOYOLA UNIVERSITY OF CHICAGO	2160 S FIRST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	8	11/8/2017	NON-COMPETING CONTINUATION	$531,387
														Subtotal = $531,387

Issue Date FY: 2017 ( Subtotal = $531,399 )
2017	2017	LOYOLA UNIVERSITY OF CHICAGO	2160 S FIRST AVE	MAYWOOD	IL	60153	COOK	USA	Allergy and Infectious Diseases Research	000	7	11/10/2016	NON-COMPETING CONTINUATION	$531,399
														Subtotal = $531,399

Issue Date FY: 2016 ( Subtotal = $544,109 )
2016	2016	LOYOLA UNIVERSITY OF CHICAGO MEDICAL CENTER	6525 NORTH SHERIDAN STREET	CHICAGO	IL	60626	COOK	USA	Allergy and Infectious Diseases Research	001	6	11/30/2015	COMPETING CONTINUATION	$544,109
2016	2014	LOYOLA UNIVERSITY OF CHICAGO MEDICAL CENTER	6525 NORTH SHERIDAN STREET	CHICAGO	IL	60626	COOK	USA	Allergy and Infectious Diseases Research	000	5	11/24/2015	NON-COMPETING CONTINUATION	$0
														Subtotal = $544,109

Issue Date FY: 2014 ( Subtotal = $393,424 )
2014	2014	LOYOLA UNIVERSITY OF CHICAGO MEDICAL CENTER	6525 NORTH SHERIDAN STREET	CHICAGO	IL	60626	COOK	USA	Allergy and Infectious Diseases Research	000	5	7/9/2014	NON-COMPETING CONTINUATION	$393,424
														Subtotal = $393,424

Issue Date FY: 2013 ( Subtotal = $369,819 )
2013	2013	LOYOLA UNIVERSITY OF CHICAGO MEDICAL CENTER	6525 NORTH SHERIDAN STREET	CHICAGO	IL	60626	COOK	USA	Allergy and Infectious Diseases Research	000	4	4/22/2013	NON-COMPETING CONTINUATION	$354,082
2013	2013	LOYOLA UNIVERSITY OF CHICAGO MEDICAL CENTER	6525 NORTH SHERIDAN STREET	CHICAGO	IL	60626	COOK	USA	Allergy and Infectious Diseases Research	001	4	5/29/2013	NON-COMPETING CONTINUATION	$15,737
														Subtotal = $369,819

Issue Date FY: 2012 ( Subtotal = $410,442 )
2012	2012	UNIVERSITY OF ILLINOIS AT CHICAGO	890 SOUTH MARSHFIELD AVENUE	CHICAGO	IL	60612	COOK	USA	Allergy and Infectious Diseases Research	000	2	4/23/2012	NON-COMPETING CONTINUATION	$407,409
2012	2012	UNIVERSITY OF ILLINOIS AT CHICAGO	890 SOUTH MARSHFIELD AVENUE	CHICAGO	IL	60612	COOK	USA	Allergy and Infectious Diseases Research	002	2	9/17/2012	NON-COMPETING CONTINUATION	-$269,355
2012	2012	LOYOLA UNIVERSITY OF CHICAGO MEDICAL CENTER	6525 NORTH SHERIDAN STREET	CHICAGO	IL	60626	COOK	USA	Allergy and Infectious Diseases Research	001	3	9/17/2012	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$272,388
														Subtotal = $410,442

Issue Date FY: 2011 ( Subtotal = $353,913 )
2011	2011	UNIVERSITY OF ILLINOIS AT CHICAGO	890 SOUTH MARSHFIELD AVENUE	CHICAGO	IL	60612	COOK	USA	Allergy and Infectious Diseases Research	000	1	5/25/2011	NEW	$353,913
														Subtotal = $353,913

Grand Total All Awards = $7,492,895

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Collaborative Integration of HCV Molecular Virology and Mathematical Modeling

Award Number: R01AI078881

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2010

PERIOD OF PERFORMANCE END DATE: 05/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer